IPX 233

Drug Profile

IPX 233

Alternative Names: IPX-233; IPX233 ER C0003; IPX233-C0001; IPX233-C0002; IPX233-T0001; IPX233-T0002

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Impax Pharmaceuticals
  • Class
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Jan 2015 Impax Pharmaceuticals terminates phase I trial of an extended release capsule in Healthy volunteers in Australia (ACTRN12614000518662)
  • 01 Aug 2014 IPX 233 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions
  • 02 Jun 2014 Impax Pharmaceuticals completes a phase I trial in Attention-deficit hyperactivity disorder (in volunteers) in Australia (ACTRN12613001073796)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top